Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Linda Cadaret is active.

Publication


Featured researches published by Linda Cadaret.


Circulation | 2005

Biventricular Assist Device Utilization for Patients with Morbid Congestive Heart Failure A Justifiable Strategy

Hiroyuki Tsukui; Jeffrey J. Teuteberg; Srinivas Murali; Dennis M. McNamara; Julianne R. Buchanan; Stephen Winowich; E. Stanford; Michael A. Mathier; Linda Cadaret; Robert L. Kormos

Background—The rationale for the use of a biventricular assist device (BiVAD) for morbid congestive heart failure (MCHF) has been questioned because of historically unacceptable rates of postimplant and post-transplant mortality as well as perceived barriers to their outpatient management. Methods and Results—All patients who received a Thoratec BiVAD from January 1990 to December 2003 at the University of Pittsburgh were studied retrospectively. There were a total of 73 patients (32% ischemic, 21% idiopathic, and 47% other) who had a BiVAD implanted. Before implantation, 100% were on ≥1 inotropic agent, and 77% had an intra-aortic balloon pump. Overall survival was 69%; 42 patients (84%) received cardiac transplantation, 5 patients (10%) were weaned, and 3 (6%) remained supported on BiVAD. If the 14 patients with postcardiotomy failure and acute myocardial infarction with shock are excluded, the overall survival improves to 75%. Five-year actuarial survival after heart transplantation was 58%. Of the 29 patients implanted before 2000, the 4-month actuarial freedom from driveline infections, bloodstream infections, and neurological events was 10%, 54%, and 48%, respectively, whereas the rates of these events for the 44 patients implanted after 2000 improved to 70%, 79%, and 80%, respectively. Since 2000, 21 (48%) patients were discharged from the hospital, of whom 38% went to an outpatient residence, 33% to a skilled nursing facility, and 29% to home. Once discharged, ≥1 readmission occurred in 45% and ≥2 readmissions in 48%. Conclusions—BiVAD support for MCHF has an acceptable overall mortality and survival to transplantation. Morbidity has been significantly reduced in the past 4 years, and management as an outpatient is achievable.


American Journal of Cardiology | 2016

Risk Factors and Outcomes of Gastrointestinal Bleeding in Left Ventricular Assist Device Recipients

Parijat S. Joy; Gagan Kumar; Achuta K. Guddati; J.K. Bhama; Linda Cadaret

Increasing use of left ventricular assist devices (LVADs) has been accompanied by rising incidence of gastrointestinal bleeding (GIB). Objectives of this study were to determine the yearly incidence of GIB in LVAD recipients, compare outcomes of continuous-flow (CF) and pulsatile-flow LVAD eras, and investigate for risk factors. The Healthcare Cost and Utilization Project-Nationwide Inpatient Sample database from 2005 to 2010 was analyzed. Primary outcome of interest was incidence of GIB in LVAD recipients. Multivariate logistic regression model was used to examine independent associations of GIB with risk factors and outcomes. An estimated 8,879 LVAD index admissions and 8,722 readmissions in LVAD recipients over 6 years were analyzed. The yearly incidence of GIB after LVAD implantation increased from 5% in 2005 to 10% in 2010. On multivariate regression analysis, the odds of GIB was 3.24 times greater (95% confidence interval 1.53 to 6.89) in the era of CF LVADs than in the era of pulsatile-flow LVADs. Compared to their younger counterparts, in LVAD recipients aged >65 years, the adjusted odds of GIB was 20.5 times greater (95% confidence interval 2.24 to 188). GIB did not significantly increase the inhospital mortality but increased the inpatient length of stay. In conclusion, the incidence of GIB in LVAD recipients has increased since the use of CF LVADs has increased, leading to greater inpatient lengths of stay and hospital charges. Older recipients of CF LVADs appear to be at a greater risk of GIB.


Journal of Heart and Lung Transplantation | 2016

High early event rates in patients with questionable eligibility for advanced heart failure therapies: Results from the Medical Arm of Mechanically Assisted Circulatory Support (Medamacs) Registry

Amrut V. Ambardekar; Rhondalyn C. Forde-McLean; M. Kittleson; Garrick C. Stewart; Maryse Palardy; Jennifer T. Thibodeau; Adam D. DeVore; Maria Mountis; Linda Cadaret; Jeffrey J. Teuteberg; Salpy V. Pamboukian; Ryan S. Cantor; JoAnn Lindenfeld

BACKGROUND The prognosis of ambulatory patients with advanced heart failure (HF) who are not yet inotrope dependent and implications for evaluation and timing for transplant or destination therapy with a left ventricular assist device (DT-LVAD) are unknown. We hypothesized that the characteristics defining eligibility for advanced HF therapies would be a primary determinant of outcomes in these patients. METHODS Ambulatory patients with advanced HF (New York Heart Association class III-IV, Interagency Registry for Mechanically Assisted Circulatory Support profiles 4-7) were enrolled across 11 centers from May 2013 to February 2015. Patients were stratified into 3 groups: likely transplant eligible, DT-LVAD eligible, and ineligible for both transplant and DT-LVAD. Clinical characteristics were collected, and patients were prospectively followed for death, transplant, and left ventricular assist device implantation. RESULTS The study enrolled 144 patients with a mean follow-up of 10 ± 6 months. Patients in the ineligible cohort (n = 43) had worse congestion, renal function, and anemia compared with transplant (n = 51) and DT-LVAD (n = 50) eligible patients. Ineligible patients had higher mortality (23.3% vs 8.0% in DT-LVAD group and 5.9% in transplant group, p = 0.02). The differences in mortality were related to lower rates of transplantation (11.8% in transplant group vs 2.0% in DT-LVAD group and 0% in ineligible group, p = 0.02) and left ventricular assist device implantation (15.7% in transplant group vs 2.0% in DT-LVAD group and 0% in ineligible group, p < 0.01). CONCLUSIONS Ambulatory patients with advanced HF who were deemed ineligible for transplant and DT-LVAD had markers of greater HF severity and a higher rate of mortality compared with patients eligible for transplant or DT-LVAD. The high early event rate in this group emphasizes the need for timely evaluation and decision making regarding lifesaving therapies.


Jacc-Heart Failure | 2017

Discordant Perceptions of Prognosis and Treatment Options Between Physicians and Patients With Advanced Heart Failure

Amrut V. Ambardekar; Jennifer T. Thibodeau; Adam D. DeVore; M. Kittleson; Rhondalyn C. Forde-McLean; Maryse Palardy; Maria Mountis; Linda Cadaret; Jeffrey J. Teuteberg; Salpy V. Pamboukian; Rongbing Xie; Lynne W. Stevenson; Garrick C. Stewart


Journal of Heart and Lung Transplantation | 2015

Early Reassessment of Ambulatory Advanced Heart Failure Detects High-Risk Trajectories Along a Dynamic Baseline

Garrick C. Stewart; Maria Mountis; M. Kittleson; Amrut V. Ambardekar; Maryse Palardy; R.C. Forde-Mc; Jennifer T. Thibodeau; J.J. Teuteberg; Salpy V. Pamboukian; Adam D. DeVore; Linda Cadaret; Ryan S. Cantor; Lynne Warner Stevenson


Journal of Heart and Lung Transplantation | 2017

(496) – Advanced Therapy Utilization and Survival in Ambulatory Patients with Advanced Heart Failure: Results from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry

V. Ambardekar; M. Kittleson; Maryse Palardy; Maria Mountis; Rhondalyn C. Forde-McLean; Adam D. DeVore; Salpy V. Pamboukian; Jennifer T. Thibodeau; J.J. Teuteberg; Linda Cadaret; R. Xie; Lynne W. Stevenson; Garrick C. Stewart


Journal of Heart and Lung Transplantation | 2016

A Novel Combined Endpoint Integrating Quality of Life Can Inform Decisions about VAD in Ambulatory Advanced Heart Failure

Garrick C. Stewart; Amrut V. Ambardekar; M. Kittleson; Maryse Palardy; Adam D. DeVore; Jennifer T. Thibodeau; J.J. Teuteberg; Linda Cadaret; Rhondalyn C. Forde-McLean; Maria Mountis; Salpy V. Pamboukian; Ryan S. Cantor; R. Xie; Lynne Warner Stevenson


Journal of Cardiac Failure | 2016

Conflicting Perceptions of Prognosis and Treatment Options between Physicians and Patients with Advanced Heart Failure: Results From the Medical Arm of Mechanically Assisted Circulatory Support (Medamacs) Registry

Amrut V. Ambardekar; Jennifer T. Thibodeau; Adam D. DeVore; M. Kittleson; Rhondalyn C. Forde-McLean; Maryse Palardy; Maria Mountis; Linda Cadaret; Jeffrey J. Teuteberg; Salpy V. Pamboukian; Lynne Warner Stevenson; Rongbing Xie; Garrick C. Stewart


Journal of Heart and Lung Transplantation | 2018

Outcomes with Ambulatory Advanced Heart Failure from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry

Amrut V. Ambardekar; M. Kittleson; Maryse Palardy; Maria Mountis; Rhondalyn C. Forde-McLean; Adam D. DeVore; Salpy V. Pamboukian; Jennifer T. Thibodeau; Jeffrey J. Teuteberg; Linda Cadaret; Rongbing Xie; Wendy C. Taddei-Peters; David C. Naftel; James K. Kirklin; Lynne Warner Stevenson; Garrick C. Stewart


Chest | 2018

Ralinepag Reduces Pulmonary Vascular Resistance (PVR) in a Phase 2 Study Confirming Preclinical Findings on Prostacyclin (IP) Receptors in Human Tissues

Ioana R. Preston; Lei Shen; Jigisha Patel; Namita Sood; Fernando Torres; Linda Cadaret; John S. Adams; Lucie H. Clapp

Collaboration


Dive into the Linda Cadaret's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Garrick C. Stewart

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Jennifer T. Thibodeau

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar

M. Kittleson

Cedars-Sinai Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Salpy V. Pamboukian

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar

Amrut V. Ambardekar

University of Colorado Denver

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge